Domestic pharmaceutical firms' strategic alliances with bioventure firms up

Published: 2002-04-11 06:56:00

Updated: 2002-04-11 06:56:00

In his recent report, a researcher Kim Seok-kwan, Industry Renovation Research Unit of Science & Technology Policy Institute, says that under the circumstances where R&D outlays of the domestic pharmaceutical firms has been in downward trends, their strategic alliances with biotechnology firms ma...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK